BioSig and Mayo Clinic Collaborate on New R&D Program to Develop Transformative AI and Machine Learning Technologies for its PURE EP™ System

    NEXT STORY
    NeurMedix Obtains FDA Authorization for Pivotal Phase 3 Alzheimer’s Trial
    PREV STORY
    Arch Biopartners Receives Ethics Committee Approval in Turkey to Dose Additional Patients in the Phase II Trial for LSALT Peptide
    Subscribe to PM360
    Print Subscription
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Global Metagenomics Market to Garner $523 Million by 2024 at 16.8% CAGR, Says Allied Market Research

    author_avatar
    NASDAQ Market News

    Spero Therapeutics to Present New Preclinical Data for SPR994 at ASM Microbe 2018

    Eighteen presentations with data across multiple pipeline candidates including data supporting SPR994’s broad spectrum ...

    author_avatar
    NASDAQ Market News

    Innovation Pharmaceuticals Opens New Clinical Site for Novel p53 Drug Candidate in Phase 2 Ovarian Cancer Trial

    BEVERLY, Mass., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals Inc., (OTCQB:IPIX) (“the Company”), ...

    author_avatar
    NASDAQ Market News